ALVO:NASDAQ, Alvotech
ALVO stock overview
Alvotech (ALVO:NASDAQ) closed at $4.62 on October 26, 2026,
up 0.87% on the day.
The stock trades 45.6% below its 52-week high of $8.50
and 57.1% above its 52-week low of $2.94.
Over the past year, it lost 43.2%.
Alvotech is part of the Health Care sector.
Key figures
- Price
- $4.62
- Day change
- +0.87%
- Volume
- 584,879
- Average volume
- 1,090,358
- Market cap
- 1B+
- 52-week range
- $2.94 – $8.50
- 50-day average
- $5.25
- 200-day average
- $4.21
Price action over the past year
In 252 trading sessions since October 24, 2025, ALVO closed higher on 120 days (48%).
Its best day was June 8, 2026 (+19.77%) and its worst was November 3, 2025 (-34.25%).
The stock moved 10% or more in a single session 11 times.
It opened at least 5% above the previous day's high 2 times.
Recent signals
ALVO news
-
Oct 21, 2026:
New Strong Sell Stocks for October 21st
-
Oct 21, 2026:
New Strong Sell Stocks for October 20th
-
Oct 20, 2026:
Alvotech's Manufacturing Progress, Simponi Launch Potential Support Recovery, UBS Says
-
Oct 20, 2026:
Alvotech shares jump premarket after FDA approves new Simlandi process
-
Oct 20, 2026:
Alvotech Receives FDA Approval for New SIMLANDI Manufacturing Process That More Than Doubles Output Per Batch
-
Oct 20, 2026:
Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch
-
Oct 16, 2026:
Alvotech Stock In Focus After Europe Filing For Eylea 8 Mg Copycat
-
Oct 14, 2026:
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
About Alvotech
Alvotech is a integrated biopharmaceutical company committed to developing and manufacturing high quality biosimilar medicines for patients globally. The company's purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.
Similar stocks
Find more stocks like ALVO with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.